EUR/USD likely to find a peak near 1.25: UBS
In a recent transaction reported to the SEC, Clay Siegall, President and CEO of Immunome Inc . (NASDAQ:IMNM), acquired 137,100 shares of the company’s common stock. The timing is notable as the stock currently trades near its 52-week low of $6.94, with InvestingPro analysis indicating the shares are currently undervalued. The purchase, executed on March 26, 2025, was made at a weighted average price of $7.29 per share, with the price range spanning from $7.16 to $7.40. The total value of this acquisition was approximately $999,459. Following this transaction, Siegall’s direct ownership in Immunome stands at 806,736 shares. With a market capitalization of $617 million and analysts setting price targets between $20 and $38, this insider purchase aligns with strong institutional confidence in the company’s potential. (InvestingPro subscribers have access to 14 additional key insights about IMNM’s financial health and market position.)
In other recent news, Immunome Inc. has been active with several significant developments. The company recently reported its fourth-quarter 2024 earnings, which aligned with previous disclosures, prompting Guggenheim Securities to adjust its price target from $35 to $25 while maintaining a Buy rating. Immunome also announced an upsized public offering of common stock, priced at $7.75 per share, expected to generate approximately $150 million in gross proceeds. This offering, managed by J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities, is intended to support ongoing research and development efforts.
The company’s pipeline is progressing, with its lead candidate, varegacestat, in a Phase 3 trial for desmoid tumors, and a Phase 1 trial for IM-1021 set to begin in early 2025. Immunome disclosed preliminary financial estimates, revealing approximately $217.3 million in cash and equivalents as of December 31, 2024. Additionally, Immunome’s Chief Financial Officer, Max Rosett, received a substantial relocation package, including a $400,000 bonus contingent on purchasing a primary residence in Bothell, Washington. These recent developments highlight Immunome’s strategic maneuvers in advancing its clinical programs and strengthening its executive team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.